Skip to main content

Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease

Digestive Diseases and Sciences volume 61, pages 1365–1374 (2016)Cite this article

Abstract

NAFLD is the leading cause of chronic liver disease in the Western world with an estimated prevalence of 20–30 %. Lifestyle interventions targeted at weight loss through dietary interventions and exercise are the most effective treatment, but only a minority of patients are able to achieve and sustain the necessary intervention targets. Weight loss of 3–5 % has been associated with a reduction of hepatic steatosis while weight loss of ≥5–7 % has correlated with resolution of NASH in some studies. Greater reductions in weight loss (≥10 %) may improve hepatic fibrosis. In the absence of weight loss, no specific diet has demonstrated superiority. Physical activity can improve hepatic steatosis and metabolic indices even without weight loss. Diet coupled with exercise can produce significant weight loss and may improve histologic components of the NAFLD activity score. While formal guidelines for diet and exercise in NAFLD are lacking, adherence to diet and exercise recommendations similar to those from the American Diabetes Association for diabetic care seems reasonable. Dietary supplementation with vitamin E in non-diabetics with biopsy-proven NASH has been shown to improve NAFLD activity score. The role for other macronutrients, micronutrients, antioxidants, and probiotics in the treatment of NAFLD remains limited.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Abbreviations

NAFLD:

Nonalcoholic fatty liver disease

NASH:

Nonalcoholic steatohepatitis

AASLD:

American Association for the Study of Liver Diseases

NAS:

Nonalcoholic fatty liver disease activity score

OR:

Odds ratio

ADA:

American Diabetes Association

MRS:

Magnetic resonance spectroscopy

HOMA:

Homeostasis model assessment

BMI:

Body mass index

ALT:

Alanine aminotransferase

AST:

Aspartate aminotransferase

MUFA:

Monounsaturated fatty acid

MET:

Metabolic equivalent

LDL:

Low-density lipoprotein

PUFA:

Polyunsaturated fatty acid

References

  1. Barrera F, George J. The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis. 2014;18:91–112.

    Article  PubMed  Google Scholar 

  2. Leite NC, Villela-Nogueira CA, Pannain VL, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 2011;31:700–706.

    Article  PubMed  Google Scholar 

  3. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–131.

    Article  PubMed  Google Scholar 

  4. Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2015. doi:10.1136/gutjnl-2015-309265.

    PubMed  Google Scholar 

  5. Stepanova M, Rafiq N, Makhlouf H, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58:3017–3023.

    CAS  Article  PubMed  Google Scholar 

  6. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–1554.

    CAS  Article  PubMed  Google Scholar 

  7. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–1362.

    CAS  Article  PubMed  Google Scholar 

  8. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009;49:80–86.

    CAS  Article  PubMed  Google Scholar 

  9. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–129.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss via lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367–378.

    Article  PubMed  Google Scholar 

  11. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55:885–904.

    CAS  Article  PubMed  Google Scholar 

  12. Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss of >/=10% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60:1024–1030.

    CAS  Article  PubMed  Google Scholar 

  13. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–1609.

    Article  PubMed  Google Scholar 

  14. Professional Practice Committee for the Standards of Medical Care in Diabetes-2016. Obesity management for the treatment of type 2 diabetes. Diabetes Care. 2016;39:S47–S51.

    Article  Google Scholar 

  15. Fan JG, Cao HX. Role of diet and nutritional management in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2013;28:81–87.

    CAS  Article  PubMed  Google Scholar 

  16. Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005;100:1072–1081.

    Article  PubMed  Google Scholar 

  17. Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med. 1970;282:829–834.

    CAS  Article  PubMed  Google Scholar 

  18. Haufe S, Engeli S, Kast P, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology. 2011;53:1504–1514.

    CAS  Article  PubMed  Google Scholar 

  19. Tendler D, Lin S, Yancy WS Jr, et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci. 2007;52:589–593.

    CAS  Article  PubMed  Google Scholar 

  20. de Luis DA, Aller R, Izaola O, et al. Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients. Nutr Hosp. 2010;25:730–735.

    PubMed  Google Scholar 

  21. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279–1290.

    CAS  Article  PubMed  Google Scholar 

  22. Elhayany A, Lustman A, Abel R, et al. A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year prospective randomized intervention study. Diabetes Obes Metab. 2010;12:204–209.

    CAS  Article  PubMed  Google Scholar 

  23. Kontogianni MD, Tileli N, Margariti A, et al. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clin Nutr. 2014;33:678–683.

    CAS  Article  PubMed  Google Scholar 

  24. McGavock JM, Anderson TJ, Lewanczuk RZ. Sedentary lifestyle and antecedents of cardiovascular disease in young adults. Am J Hypertens. 2006;19:701–707.

    Article  PubMed  Google Scholar 

  25. Zhu S, St-Onge MP, Heshka S, Heymsfield SB. Lifestyle behaviors associated with lower risk of having the metabolic syndrome. Metab Clin Exp. 2004;53:1503–1511.

    CAS  Article  PubMed  Google Scholar 

  26. Church TS, Kuk JL, Ross R, Priest EL, Biltoft E, Blair SN. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology. 2006;130:2023–2030.

    CAS  Article  PubMed  Google Scholar 

  27. Kang H, Greenson JK, Omo JT, et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol. 2006;101:2247–2253.

    CAS  Article  PubMed  Google Scholar 

  28. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology. 2008;48:1791–1798.

    Article  PubMed  Google Scholar 

  29. Krasnoff JB, Painter PL, Wallace JP, et al. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology. 2008;47:1158–1166.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. Kistler KD, Brunt EM, Clark JM, et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011;106:460–468. quiz 9.

    Article  PubMed  PubMed Central  Google Scholar 

  31. St George A, Bauman A, Johnston A, et al. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology. 2009;50:68–76.

    CAS  Article  PubMed  Google Scholar 

  32. Keating SE, Hackett DA, George J, et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57:157–166.

    CAS  Article  PubMed  Google Scholar 

  33. Eckard C, Cole R, Lockwood J, et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Ther Adv Gastroenterol. 2013;6:249–259.

    Article  Google Scholar 

  34. Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60:1278–1283.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Zelber-Sagi S, Buch A, Yeshua H, et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. World J Gastroenterol. 2014;20:4382–4392.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Wu T, Gao X, Chen M, van Dam RM. Long-term effectiveness of diet-plus-exercise interventions vs. diet-only interventions for weight loss: a meta-analysis. Obes Rev. 2009;10:313–323.

    CAS  Article  PubMed  Google Scholar 

  37. Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2009;30:999–1009.

    CAS  Article  PubMed  Google Scholar 

  38. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103–107.

    CAS  Article  PubMed  Google Scholar 

  39. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146:1513–1524.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  40. Yki-Jarvinen H. Nutritional modulation of non-alcoholic fatty liver disease and insulin resistance. Nutrients. 2015;7:9127–9138.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Allard JP, Aghdassi E, Mohammed S, et al. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol. 2008;48:300–307.

    CAS  Article  PubMed  Google Scholar 

  42. Gerhard GT, Ahmann A, Meeuws K, McMurry MP, Duell PB, Connor WE. Effects of a low-fat diet compared with those of a high-monounsaturated fat diet on body weight, plasma lipids and lipoproteins, and glycemic control in type 2 diabetes. Am J Clin Nutr. 2004;80:668–673.

    CAS  PubMed  Google Scholar 

  43. Bozzetto L, Prinster A, Annuzzi G, et al. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care. 2012;35:1429–1435.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  44. Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59:138–143.

    CAS  Article  PubMed  Google Scholar 

  45. Araya J, Rodrigo R, Videla LA, et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci. 2004;106:635–643.

    CAS  Article  PubMed  Google Scholar 

  46. Clarke SD. Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am J Physiol Gastrointest Liver Physiol. 2001;281:G865–G869.

    CAS  PubMed  Google Scholar 

  47. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83:1505S–1519S.

    CAS  PubMed  Google Scholar 

  48. Parker HM, Johnson NA, Burdon CA, Cohn JS, O’Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;56:944–951.

    CAS  Article  PubMed  Google Scholar 

  49. Dasarathy S, Dasarathy J, Khiyami A, et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2015;49:137–144.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  50. Nogueira MA, Oliveira CP, Ferreira Alves VA, et al. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2015. doi:10.1016/j.clnu.2015.05.001.

    PubMed  Google Scholar 

  51. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  52. Vos MB, Kimmons JE, Gillespie C, Welsh J, Blanck HM. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med. 2008;10:160.

    PubMed  PubMed Central  Google Scholar 

  53. Tappy L, Le KA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010;90:23–46.

    CAS  Article  PubMed  Google Scholar 

  54. Basaranoglu M, Basaranoglu G, Bugianesi E. Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr. 2015;4:109–116.

    PubMed  PubMed Central  Google Scholar 

  55. Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1961–1971.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  56. Chung M, Ma J, Patel K, et al. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr. 2014;100:833–849.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  57. Kanerva N, Sandboge S, Kaartinen NE, Mannisto S, Eriksson JG. Higher fructose intake is inversely associated with risk of nonalcoholic fatty liver disease in older Finnish adults. Am J Clin Nutr. 2014;100:1133–1138.

    CAS  Article  PubMed  Google Scholar 

  58. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659–1668.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  59. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46.

    CAS  Article  PubMed  Google Scholar 

  60. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:2485–2490.

    CAS  Article  PubMed  Google Scholar 

  61. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology. 2008;48:119–128.

    CAS  Article  PubMed  Google Scholar 

  62. Loftfield E, Freedman ND, Graubard BI, et al. Association of coffee consumption with overall and cause-specific mortality in a large US prospective cohort study. Am J Epidemiol. 2015;182:1010–1022.

    PubMed  Google Scholar 

  63. Corrao G, Zambon A, Bagnardi V, D’Amicis A, Klatsky A, Collaborative SG. Coffee, caffeine, and the risk of liver cirrhosis. Ann Epidemiol. 2001;11:458–465.

    CAS  Article  PubMed  Google Scholar 

  64. Johnson S, Koh WP, Wang R, Govindarajan S, Yu MC, Yuan JM. Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Cancer Causes Control. 2011;22:503–510.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Graeter T, Niedermayer PC, Mason RA, et al. Coffee consumption and NAFLD: a community based study on 1223 subjects. BMC Res Notes. 2015;8:640.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Zelber-Sagi S, Salomone F, Webb M, et al. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. Transl Res. 2015;165:428–436.

    CAS  Article  PubMed  Google Scholar 

  67. Catalano D, Martines GF, Tonzuso A, Pirri C, Trovato FM, Trovato GM. Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2010;55:3200–3206.

    CAS  Article  PubMed  Google Scholar 

  68. Gutierrez-Grobe Y, Chavez-Tapia N, Sanchez-Valle V, et al. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Ann Hepatol. 2012;11:350–355.

    CAS  PubMed  Google Scholar 

  69. Molloy JW, Calcagno CJ, Williams CD, et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55:429–436.

    CAS  Article  PubMed  Google Scholar 

  70. Aqel B, DiBaise JK. Role of the gut microbiome in nonalcoholic fatty liver disease. Nutr Clin Pract. 2015;30:780–786.

    Article  PubMed  Google Scholar 

  71. Wong VW, Won GL, Chim AM, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013;12:256–262.

    CAS  PubMed  Google Scholar 

  72. Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276–1285.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  73. Eslamparast T, Poustchi H, Zamani F, et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99:535–542.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Medicine, San Antonio Military Medical Center, 3551 Roger Brooke Drive, JBSA - Fort Sam Houston, San Antonio, TX, 78234-4504, USA

    William N. Hannah Jr.

  2. Division of Gastroenterology, San Antonio Military Medical Center, 3551 Roger Brooke Drive, JBSA - Fort Sam Houston, San Antonio, TX, 78234-4504, USA

    Stephen A. Harrison

Authors
  1. William N. Hannah Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen A. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen A. Harrison.

Ethics declarations

Conflict of interest

Dr. Hannah has no financial disclosures to report. Dr. Harrison is an advisor for Fibrogen, Chronic Liver Disease Foundation, NGM Biopharmaceuticals, Merck, Pfizer, Nimbus Discovery, Zafgen, and Intercept. He is a speaker for Gilead, Merck, and Abbvie.

Additional information

Disclaimer The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of San Antonio Military Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, Department of Defense or the U.S. Government.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hannah, W.N., Harrison, S.A. Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 61, 1365–1374 (2016). https://doi.org/10.1007/s10620-016-4153-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-016-4153-y

Keywords

  • Nonalcoholic fatty liver disease
  • Weight loss
  • Exercise
  • Probiotics